Beatriz Berzal-Herranz

TL;DR: The present work analyses the anti-HCV potential of HH363-24, an in vitro selected molecule composed of a catalytic RNA cleaving domain with an extension at the 3' end that acts as aptamer for the viral 5'UTR.

TL;DR: A non-viral vector based on solid lipid nanoparticles bearing hyaluronic acid, protamine and a short hairpin RNA targeted to the Internal Ribosome Entry Site (IRES) of the HCV is shown for the first time to silence a HCV replicon.

TL;DR: Inhibition assays showed that the selected RNAs significantly inhibit the replication of a subgenomic HCV replicon in Huh-7 cell cultures, highlighting the potential of aptamer RNA molecules as therapeutic antiviral agents.

TL;DR: The feasibility of using in vitro selection strategies for obtaining improved RNA molecules with potential clinical applications is highlighted, including the anti-HCV chimeric inhibitor RNA HH363-10, which has a hammerhead catalytic domain and an aptamer RNA domain.

TL;DR: The present data show that the CRE promotes a defect in polysome production, and hinders the assembly of the 80S complex, likely through the direct, high affinity recruitment of the 40S ribosomal subunit, which supports a model in which the CRE-mediated inhibition of viral translation is a multifactorial process defined by the establishment of long-range RNA-RNA interactions.